

Disclosures

OPTIMUM study (NCT02425644) is supported by Actelion Pharmaceuticals, Part of Janssen Pharmaceutical Companies, Allschwil, Switzerland

Ludwig Kappos's institution (University Hospital Basel) received in the last 3 years and used exclusively for research support at the Department: steering committee, advisory board, and consultancy fees from Actelion, Almirall, Bayer, Biogen, Celgene/Receptos, Eisai, Genzyme, Japan Tobacco, Merck, Minoryx, Novartis, F. Hoffmann-La Roche Ltd, Sanofi Aventis, Santhera, Teva, and license fees for Neurostatus-UHB products; For educational activities the institution received payments and honoraria from Allergan, Almirall, Baxalta, Bayer, Biogen, CSL-Behring, Desitin, Excemed, Genzyme, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Teva; the Research of the MS Center in Basel has been supported by grants from Bayer, Biogen, Novartis, the Swiss MS Society, the Swiss National Research Foundation, Inno-Suisse, the European Union, and Roche Research Foundations.

Michel Burcklen, Brian Hennessy, Philippe Linscheid and Hilke Kracker are employees of Actelion Pharmaceuticals, a Janssen Pharmaceutical company of Johnson & Johnson. Brian Hennessy holds stock in Johnson & Johnson, Novo Nordisk, Arena Pharmaceuticals and Galapagos. Michel Burcklen and Hilke Kracker hold stocks in Johnson & Johnson.

Tatiana Scherz is an employee of Actelion Pharmaceuticals, a Janssen Pharmaceutical company of Johnson & Johnson and a former employee of Novartis Pharma AG. She holds stock in Johnson & Johnson.

Mark Freedman has received honoraria from Actelion, Bayer Healthcare, Biogen Idec, Chugai, Clene Nanomedicine, EMD Canada, Genzyme, Hoffman La-Roche, MedDay, Merck Serono, Novartis, Sanofi-Aventis, Teva Canada Innovation, and research support from Genzyme.

Robert Fox has received personal consulting fees from Actelion, Biogen, Celgene, EMD Serono, Genentech, Immunic, Novartis, Sanofi, Teva, and TG Therapeutics; also served on advisory committees for Actelion, Biogen, Immunic, and Novartis, and received clinical trial contract and research grant funding from Biogen and Novartis.

Eva Havrdova has received honoraria from Actelion, Biogen, Genzyme-Sanofi, Novartis, Roche, and research support from Biogen, Genzyme-Sanofi, Novartis, Roche.

Reinhard Hohlfeld has received honoraria from Actelion, Biogen, Genzyme-Sanofi, Novartis, Roche, and research support from Biogen, Genzyme-Sanofi, Novartis, Roche.

Fred Lublin sources of funding for research: Novartis; Actelion; Biogen; Sanofi, NMSS, NIH; Brainstorm Cell Therapeutics; Consulting Agreements/Advisory Boards/DSMB: Biogen; EMD Serono; Novartis; Teva; Actelion/Janssen; Sanofi/Genzyme; Acorda; Roche/Genentech; MedImmune/ Viela Bio; Receptos/Celgene; TG Therapeutics; Medday; Atara Biotherapeutics; Polpharma; Mapi Pharma; Innate Immunotherapeutics; Apitope; Orion Biotechnology; Brainstorm Cell Therapeutics; Jazz Pharmaceuticals; GW Pharma; Mylan; Immunic; Population Council; Avotres; Speaker: Sanofi (non-promotional).

Xavier Montalban received speaking honoraria and travel expenses for scientific meetings, has been a steering committee member of clinical trials or participated in advisory boards of clinical trials in the

past 3 years with Actelion, Alexion, Bayer, Biogen, Celgene, EMD Serono, EXCEMED, Genzyme, MedDay, Merck, MSIF, Nervgen, NMSS, Novartis, Roche, Sanofi-Genzyme, Teva Pharmaceutical, and TG Therapeutics.

Carlo Pozzilli has served on scientific advisory boards for Novartis, Merck, Biogen, Sanofi, Genzyme, Teva, Actelion and funding for travel and speaker honoraria from Biogen, Teva, Sanofi Genzyme, Actelion and Novartis, and research support from Biogen, Teva, Novartis and Genzyme

Magdalena Pirozek-Lawniczek was an employee of Actelion Pharmaceuticals, Part of Janssen Pharmaceutical companies of Johnson & Johnson at the time of study.

Lisa Ford is an employee of Janssen Research & Development, LLC and holds company stocks

Jens Wuerfel is the CEO of MIAC AG Basel, Switzerland. He served on scientific advisory boards of Actelion, Biogen, Genzyme-Sanofi, Idorsia, Novartis, and Roche. He is or was supported by grants of the EU (Horizon2020), German Federal Ministries of Education and Research (BMBF) and of Economic Affairs and Energy (BMWI).

Till Sprenger's institution has received honoraria for speaking and consultation from Actelion, Biogen Idec, Desitin, Eli Lilly, Novartis, Sanofi Genzyme, Electrocore, Merck and Teva.